18 Dec, 2023 Crossing the Blurred Line Between Brands and Generics By Aziz Burgy Ian Swan Clients often ask if a law firm can represent both brand and generic drug manufacturers. It’s a reasonable question, particularly when...
15 Dec, 2023 Reflecting on 2023 Events: Diversity, Equity, and Inclusion By Axinn Events We proudly partnered with several diversity-focused organizations throughout 2023, supporting events that brought together attorneys from...
15 Dec, 2023 The Inflation Reduction Act’s First Potential Impact on Biosimilars By Ted Mathias Ross Blau Chantelle Ankerman On October 31, 2023, FDA approved Amgen’s Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Janssen’s Stelara...
14 Dec, 2023 FTC Spoke, Kaleo and Impax Listened: Orange Book Patent Delistings Begin By Chad Landmon Ross Blau As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA’s...
13 Dec, 2023 Reading Tea Leaves: Oral Arguments in Motorola v. Hytera and the Extraterritorial Reach of the DTSA By Nicholas Duffee Matt Murphy Last week, the Seventh Circuit heard arguments in Motorola Solutions, Inc. v. Hytera Communications Corp. concerning when, if at all,...
11 Dec, 2023 The Skinny on Infringement of Method of Treatment Claims By Rebecca Clegg In Hatch-Waxman litigation, method of treatment patents present unique infringement issues. Because generic drug manufacturers typically...
08 Dec, 2023 HHS to Go a March-In' By Chad Landmon Following years of discussion and pressure being applied by certain policymakers (including Senate HELP Committee Chair Bernie Sanders),...
06 Dec, 2023 Clarity May Be Around the Corner for Antitrust Scrutiny of Reverse Payment Settlements By Ted Mathias Caroline Boisvert In the ten years since the Supreme Court ruled in Federal Trade Commission v. Actavis that reverse payment settlements—or settlements...